Harness the power of STIVARGA® (regorafenib)

"Healthcare Professional site for STIVARGA (regorafenib) Tablets. Visit hcp.stivarga-us.com to see full Safety and Prescribing Information, Including Boxed Warning."

Harness the proven efficacy of STIVARGA to maximize potential overall survival (OS) for your previously treated patients with mCRC

In the pivotal CORRECT trial, STIVARGA demonstrated a median OS of 6.4 months vs 5.0 months with placebo for previously treated patients with mCRC1

Significant improvement in OS1*

STIVARGA (regorafenib) OS study data. Visit hcp.stivarga-us.com to see full safety and Prescribing Information, including Boxed Warning.

23% reduction in the risk of
death with STIVARGA1

HR: 0.77
(95% CI, 0.64-0.94) P=0.0102

23% reduction in the risk of
death with STIVARGA1

HR: 0.77
(95% CI, 0.64-0.94) P=0.0102

CORRECT (COloRectal cancer treated with REgorafenib or plaCebo after failure of standard Therapy) was a large, international, placebo-controlled, double-blind, randomized (2:1), phase 3 trial that evaluated the efficacy and safety of STIVARGA in patients with mCRC who had progressed after all approved standard therapies (N=760).1,2

  • STIVARGA improved OS in CORRECT, which included patients with historically collected KRAS status (N=729)1
    • Historical KRAS status was assessed (59% mutant, 41% KRAS wild-type)
  • There were 275 deaths out of 505 patients treated with STIVARGA (55%) vs 157 deaths out of 255 patients treated with placebo (62%)1

Cytotoxic therapy in CORRECT

In CORRECT, patients were able to receive cytotoxic therapy following treatment with STIVARGA2,3

CORRECT trial: 26% of patients received cytotoxic therapy after STIVARGA2,3

 STIVARGA, n (%)Placebo, n (%)
Systemic anticancer treatment during CORRECT trial follow-up(n=505)(n=255)
Patients with ≥1 medication131 (26)76 (30)
Any antineoplastic or immunomodulation agent130 (26)74 (29)
Systemic anticancer treatment during CORRECT trial follow-upSTIVARGA, n (%)
(n=505)
Placebo, n (%)
(n=255)
Patients with ≥1 medication131 (26)76 (30)
Any antineoplastic or immunomodulation agent130 (26)74 (29)

STIVARGA significantly improved progression-free survival (PFS)

In the pivotal CORRECT trial, STIVARGA demonstrated a 51% reduction in the risk of disease progression or death1,2

Significant improvement in PFS1,2†

"STIVARGA (regorafenib) PFS trial data. Visit hcp.stivarga-us.com to see full safety and Prescribing Information, including Boxed Warning."

51% reduction in the risk of
disease progression or death in CORRECT1,2

HR: 0.49
(95% CI, 0.42-0.58) P<0.0001

51% reduction in the risk of
disease progression or death in CORRECT1,2

HR: 0.49
(95% CI, 0.42-0.58) P<0.0001

Disease control rate (DCR)

Disease control with 41% of patients treated with STIVARGA vs 15% with placebo2

  • DCR included a 41% stable disease rate and a 1% partial response rate in the STIVARGA arm (n=207/505) vs a 15% stable disease rate and a 0.4% partial response rate in the placebo arm (n=38/255)2
    • Disease control is defined as proportion of patients with a best response of complete or partial response or stable disease; assessment of stable disease had to be made at least 6 weeks after randomization

CORRECT trial study design

Multicenter, randomized, double-blind, placebo-controlled, phase 3 trial2

A large, international, phase 3, double-blind, randomized trial involving 760 patients1,2

STIVARGA (regorafenib) study design. Visit hcp.stivarga-us.com to see full safety and Prescribing Information, including Boxed Warning.
  • Study arms abbreviated as STIVARGA and placebo throughout this website
  • Stratification: Prior treatment with anti-VEGF drugs, time from diagnosis of mCRC, and geographical region2
  • Treatment continued until disease progression or unacceptable toxicity2
  • Tumors were assessed every 8 weeks by RECIST 1.1 criteria2
  • No crossover between treatment groups was allowed2

CORRECT trial patient population

Most demographics and disease characteristics were similar between arms in the CORRECT trial

Baseline characteristics2

 STIVARGA 
(n=505)
Placebo 
(n=255)
Median age, y6161
Sex  
Male62%60%
Female38%40%
Disease site  
Colon64%68%
Rectum30%27%
Both6%5%
Historical KRAS status  
Mutated54%62%
Race  
White78%79%
Black or African American1%3%
Asian15%14%
Other or not specified6%4%
ECOG performance status  
ECOG PS 052%57%
ECOG PS 148%43%